Purity 99% Letrozole Femara Raw Powder CAS 112809-51-5 For Infertility Treatment

Purity 99% Letrozole Femara Raw Powder CAS 112809-51-5 For Infertility Treatment

Application:

Letrozole is a new generation of highly selective aromatase inhibitors. It is a synthetic benzyltriazole derivative. By inhibiting aromatase, it reduces the level, thereby eliminating the stimulating effect of medicine on tumor growth. The in vivo activity is 150-250 times stronger than the first-generation aromatase inhibitor aminoglutethimide. Because of its high selectivity, it does not affect the function of glucocorticoids, mineralocorticoids and thyroid gland, and large doses have no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index. Various preclinical studies have shown that letrozole has no potential toxicity to various systems and target organs of the body, no mutagenicity and carcinogenicity, and has less toxic and side effects, and is well tolerated. Compared with drugs, the antitumor effect is stronger. It is suitable for the treatment of postmenopausal patients with advanced breast cancer who are ineffective therapy and the treatment of early breast cancer.

Letrozole has been used by fertility doctors for ovarian stimulation since 2001 because it has fewer side effects than Clomiphene Clomiphene (Clomiphene) and is less likely to cause multiple pregnancies. A Canadian study presented at the 2005 American Society for Reproductive Medicine meeting suggested that letrozole may increase the risk of birth defects. A more detailed ovulation induction follow-up study found that letrozole had a significantly lower overall incidence of congenital malformations and chromosomal abnormalities of 2.4% (1.2% severely malformed) compared with clomiphene clomiphene control group. 4.8% (3.0% severely deformed). Letrozole use is legal in many countries, including the United States and the United Kingdom.

The effects of letrozole have been shown to be used in combination with misoprostol as a pretreatment for termination of pregnancy. It can be used in place of mifepristone, which is expensive and unavailable in many countries.

Letrozole is sometimes used as a drug to treat gynecomastia, although it may be most effective if caught early (as in users of anabolic ).

Letrozole has also been shown to delay growth plate fusion in mice. Letrozole has been shown to be effective in an adolescent boy with short stature when given in combination with growth hormone.

COA:

Application

1. Treatment of postmenopausal advanced breast cancer ( receptor, progesterone receptor positive or unknown receptor status), mostly used for second-line treatment after failure of therapy;

2. For the first-line treatment of locally advanced or diffuse postmenopausal breast cancer (foreign data);

3. Extended adjuvant therapy for postmenopausal breast cancer patients who have received tamoxifen standard adjuvant therapy for 5 years (foreign data);

4. For postoperative adjuvant therapy of hormone-positive early breast cancer patients.